• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Signal Transduct Target Ther . P21-activated kinase 1 (PAK1)-mediated cytoskeleton rearrangement promotes SARS-CoV-2 entry and ACE2 autophagic degra

tetano

Editor, Senior Moderator
Signal Transduct Target Ther


. 2023 Oct 9;8(1):385.
doi: 10.1038/s41392-023-01631-0. P21-activated kinase 1 (PAK1)-mediated cytoskeleton rearrangement promotes SARS-CoV-2 entry and ACE2 autophagic degradation

Ming Liu[SUP] #[/SUP][SUP] 1 [/SUP], Bingtai Lu[SUP] #[/SUP][SUP] 2 [/SUP], Yue Li[SUP] #[/SUP][SUP] 1 [/SUP], Shuofeng Yuan[SUP] #[/SUP][SUP] 3 4 5 [/SUP], Zhen Zhuang[SUP] #[/SUP][SUP] 6 [/SUP], Guangyu Li[SUP] 1 [/SUP], Dong Wang[SUP] 6 [/SUP], Liuheyi Ma[SUP] 1 [/SUP], Jianheng Zhu[SUP] 1 [/SUP], Jinglu Zhao[SUP] 7 [/SUP], Chris Chung-Sing Chan[SUP] 3 5 [/SUP], Vincent Kwok-Man Poon[SUP] 3 5 [/SUP], Kenn Ka-Heng Chik[SUP] 3 5 [/SUP], Zhiyao Zhao[SUP] 1 [/SUP], Huifang Xian[SUP] 1 [/SUP], Jingxian Zhao[SUP] 6 [/SUP], Jincun Zhao[SUP] 8 [/SUP], Jasper Fuk-Woo Chan[SUP] 9 10 11 12 [/SUP], Yuxia Zhang[SUP] 13 14 15 [/SUP]



Affiliations
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has had a significant impact on healthcare systems and economies worldwide. The continuous emergence of new viral strains presents a major challenge in the development of effective antiviral agents. Strategies that possess broad-spectrum antiviral activities are desirable to control SARS-CoV-2 infection. ACE2, an angiotensin-containing enzyme that prevents the overactivation of the renin angiotensin system, is the receptor for SARS-CoV-2. ACE2 interacts with the spike protein and facilitates viral attachment and entry into host cells. Yet, SARS-CoV-2 infection also promotes ACE2 degradation. Whether restoring ACE2 surface expression has an impact on SARS-CoV-2 infection is yet to be determined. Here, we show that the ACE2-spike complex is endocytosed and degraded via autophagy in a manner that depends on clathrin-mediated endocytosis and PAK1-mediated cytoskeleton rearrangement. In contrast, free cellular spike protein is selectively cleaved into S1 and S2 subunits in a lysosomal-dependent manner. Importantly, we show that the pan-PAK inhibitor FRAX-486 restores ACE2 surface expression and suppresses infection by different SARS-CoV-2 strains. FRAX-486-treated Syrian hamsters exhibit significantly decreased lung viral load and alleviated pulmonary inflammation compared with untreated hamsters. In summary, our findings have identified novel pathways regulating viral entry, as well as therapeutic targets and candidate compounds for controlling the emerging strains of SARS-CoV-2 infection.


 
Back
Top Bottom